Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Atara BiotherapeuticsVaxcyteAlectorImmunovantAdverum Biotechnologies
SymbolNASDAQ:ATRANASDAQ:PCVXNASDAQ:ALECNASDAQ:IMVTNASDAQ:ADVM
Price Information
Current Price$13.85$19.90$17.57$15.92$9.17
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.41.71.31.81.7
Analysis Score3.43.53.54.53.4
Community Score2.82.92.43.72.4
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.80.82.5
Earnings & Valuation Score0.60.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$35.88$48.00$33.67$45.60$23.50
% Upside from Price Target159.03% upside141.21% upside91.61% upside186.52% upside156.27% upside
Trade Information
Market Cap$1.16 billion$1.02 billion$1.40 billion$1.56 billion$896.79 million
Beta2.65N/A1.08N/A1.72
Average Volume864,474412,592638,2761,481,024839,244
Sales & Book Value
Annual RevenueN/AN/A$21.22 millionN/A$250,000.00
Price / SalesN/AN/A65.89N/A3,587.16
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.37 per shareN/A$2.83 per share$1.45 per share$2.71 per share
Price / BookN/AN/A6.21N/A3.38
Profitability
Net Income$-290,980,000.00$-50,270,000.00$-105,390,000.00$-66,390,000.00$-64,490,000.00
EPS($5.67)N/A($1.71)($1.54)($1.01)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-757.78%N/AN/A
Return on Equity (ROE)-94.86%N/A-53.86%-34.80%-32.23%
Return on Assets (ROA)-82.17%N/A-31.44%-32.38%-28.02%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio9.41%10.12%6.61%35.15%28.53%
Quick Ratio9.41%10.12%6.61%35.15%28.53%
Ownership Information
Institutional Ownership PercentageN/A74.08%61.50%40.21%97.41%
Insider Ownership Percentage4.30%N/A13.90%0.24%12.40%
Miscellaneous
Employees4375817142167
Shares Outstanding83.62 million51.33 million79.58 million97.97 million97.80 million
Next Earnings Date5/5/2021 (Estimated)7/5/2021 (Estimated)5/12/2021 (Estimated)7/5/2021 (Estimated)5/27/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
For Adverum Biotechnologies Inc. [ADVM], Analyst sees a rise to $13. What next?For Adverum Biotechnologies Inc. [ADVM], Analyst sees a rise to $13. What next?
dbtnews.com - April 12 at 1:31 PM
Adverum Biotechnologies (NASDAQ:ADVM) Sets New 1-Year Low at $8.98Adverum Biotechnologies (NASDAQ:ADVM) Sets New 1-Year Low at $8.98
americanbankingnews.com - April 12 at 9:22 AM
What You Missed About Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Stock This WeekWhat You Missed About Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Stock This Week
stocksregister.com - April 12 at 8:31 AM
Adverum Biotechnologies (NASDAQ:ADVM) Shares Down 4.8% Adverum Biotechnologies (NASDAQ:ADVM) Shares Down 4.8%
americanbankingnews.com - April 9 at 1:40 PM
Issues Important Note to Shareholders to Ensure Shares Are Voteable at the 2021 Annual MeetingIssues Important Note to Shareholders to Ensure Shares Are Voteable at the 2021 Annual Meeting
morningstar.com - April 8 at 12:09 PM
The Sonic Fund II, L.P. Files Preliminary Proxy Statement Relating to the Election of Highly Qualified Independent Directors at the 2021 Annual Meeting of Adverum Biotechnologies, Inc.The Sonic Fund II, L.P. Files Preliminary Proxy Statement Relating to the Election of Highly Qualified Independent Directors at the 2021 Annual Meeting of Adverum Biotechnologies, Inc.
finance.yahoo.com - April 8 at 12:09 PM
Adverum Biotechnologies (NASDAQ:ADVM) Shares Gap Up to $10.08Adverum Biotechnologies (NASDAQ:ADVM) Shares Gap Up to $10.08
americanbankingnews.com - April 5 at 11:40 AM
Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 ...Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 ...
apnews.com - March 31 at 2:24 AM
Adverum Biotechnologies (NASDAQ:ADVM) Shares Gap Down to $9.43Adverum Biotechnologies (NASDAQ:ADVM) Shares Gap Down to $9.43
americanbankingnews.com - March 30 at 11:45 AM
Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 TrialsAdverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials
finance.yahoo.com - March 30 at 11:21 AM
Adverum Biotechnologies (NASDAQ:ADVM) Shares Gap Up Following Insider Buying ActivityAdverum Biotechnologies (NASDAQ:ADVM) Shares Gap Up Following Insider Buying Activity
americanbankingnews.com - March 25 at 10:32 AM
Adverum Biotechnologies Inc (ADVM) CEO and Director Laurent Fischer Bought $98,800 of SharesAdverum Biotechnologies Inc (ADVM) CEO and Director Laurent Fischer Bought $98,800 of Shares
finance.yahoo.com - March 24 at 11:40 PM
Insider Buying: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) CEO Purchases 10,000 Shares of StockInsider Buying: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) CEO Purchases 10,000 Shares of Stock
americanbankingnews.com - March 24 at 8:22 PM
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Buy" from AnalystsAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Buy" from Analysts
americanbankingnews.com - March 21 at 4:28 PM
We do not bluff: Peninsula biotech company in showdown with hedge fund'We do not bluff': Peninsula biotech company in showdown with hedge fund
bizjournals.com - March 19 at 2:49 PM
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 19 at 8:57 AM
The Daily Biotech Pulse: Translate Bios Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On NasdaqThe Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq
markets.businessinsider.com - March 18 at 8:48 AM
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value CreationAdverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
finance.yahoo.com - March 17 at 7:22 PM
Noteworthy Friday Option Activity: T, ADVM, SWKSNoteworthy Friday Option Activity: T, ADVM, SWKS
nasdaq.com - March 5 at 7:38 PM
Adverum Biotechnologies, Incs (ADVM) CEO Laurent Fischer on Q4 2020 Results - Earnings Call TranscriptAdverum Biotechnologies, Inc's (ADVM) CEO Laurent Fischer on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 3 at 11:23 PM
Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene ...Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene ...
apnews.com - March 1 at 6:31 PM
Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial ResultsAdverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results
finance.yahoo.com - February 22 at 7:39 PM
Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of DirectorsAdverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors
finance.yahoo.com - February 22 at 9:38 AM
Adverum Appoints Christopher J. DeRespino as Chief Business OfficerAdverum Appoints Christopher J. DeRespino as Chief Business Officer
finance.yahoo.com - February 18 at 5:56 PM
Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in ...Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in ...
apnews.com - February 11 at 8:49 AM
DateCompanyBrokerageAction
3/2/2021Atara BiotherapeuticsWilliam BlairReiterated Rating
3/2/2021Atara BiotherapeuticsCitigroupUpgrade
12/9/2020Atara BiotherapeuticsSmith Barney CitigroupDowngrade
12/9/2020Atara BiotherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngrade
12/8/2020Atara BiotherapeuticsHC WainwrightReiterated Rating
12/7/2020Atara BiotherapeuticsStifel NicolausBoost Price Target
11/23/2020Atara BiotherapeuticsMizuhoBoost Price Target
9/14/2020Atara BiotherapeuticsCanaccord GenuityBoost Price Target
6/30/2020Atara BiotherapeuticsEvercore ISIInitiated Coverage
5/12/2020Atara BiotherapeuticsJPMorgan Chase & Co.Boost Price Target
12/10/2019Atara BiotherapeuticsCowenReiterated Rating
8/14/2020VaxcyteNeedham & Company LLCReiterated Rating
7/7/2020VaxcyteBank of AmericaInitiated Coverage
7/7/2020VaxcyteJefferies Financial GroupInitiated Coverage
7/7/2020VaxcyteCantor FitzgeraldInitiated Coverage
7/29/2020AlectorBarclaysLower Price Target
6/4/2020AlectorMorgan StanleyBoost Price Target
4/28/2020AlectorThe Goldman Sachs GroupInitiated Coverage
11/27/2019AlectorBTIG ResearchInitiated Coverage
3/4/2019AlectorSVB LeerinkInitiated Coverage
2/3/2021ImmunovantRaymond JamesLower Price Target
2/2/2021ImmunovantCredit Suisse GroupDowngrade
11/13/2020ImmunovantTruistBoost Price Target
11/13/2020ImmunovantRobert W. BairdBoost Price Target
11/12/2020ImmunovantChardan CapitalBoost Price Target
10/28/2020ImmunovantUBS GroupInitiated Coverage
10/12/2020ImmunovantGuggenheimInitiated Coverage
10/6/2020ImmunovantLifesci CapitalReiterated Rating
10/2/2020ImmunovantCSFBInitiated Coverage
8/10/2020Adverum BiotechnologiesPiper SandlerBoost Price Target
6/16/2020Adverum BiotechnologiesRoyal Bank of CanadaBoost Price Target
5/5/2020Adverum BiotechnologiesSunTrust BanksUpgrade
1/13/2020Adverum BiotechnologiesPiper Jaffray CompaniesBoost Price Target
(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.